Cancer Research Cancer Health Disparities Conference 2009 SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valmori, D.
Right arrow Articles by Rimoldi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valmori, D.
Right arrow Articles by Rimoldi, D.
[Cancer Research 61, 509-512, January 15, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Frequent Cytolytic T-Cell Responses to Peptide MAGE-A10254–262 in Melanoma1

Danila Valmori1, Valérie Dutoit, Verena Rubio-Godoy2, Céline Chambaz, Danielle Liénard, Philippe Guillaume, Pedro Romero, Jean-Charles Cerottini and Donata Rimoldi

Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital, 1011 Lausanne, Switzerland [D. V., V. D., V. R-G., D. L., P. R., J-C. C.]; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, 1066 Epalinges, Switzerland [C. C., D. R.]; and Multidisciplinary Oncology Center, University Hospital, 1011 Lausanne, Switzerland [P. G.]

MAGE genes encode tumor-specific shared antigens that are among the most interesting candidates for cancer vaccines. Despite extensive studies, however, CD8+ T-cell responses to MAGE-derived epitopes have been detected only occasionally in cancer patients, even after vaccination. In contrast with these findings, we report here that HLA-A2 melanoma patients respond frequently to the recently identified peptide MAGE-A10254–262. Indeed, as assessed by staining with fluorescent HLA-A2/peptide MAGE-A10254–262 tetramers, CD8+ T cells directed against this peptide were readily detectable in a large proportion of HLA-A2+ melanoma patients. These results provide new insight into the immunogenicity of MAGE antigens and underline the potential usefulness of MAGE-A10 peptide-based cancer vaccines.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. Sartorius, P. Pisu, L. D'Apice, L. Pizzella, C. Romano, G. Cortese, A. Giorgini, A. Santoni, F. Velotti, and P. De Berardinis
The Use of Filamentous Bacteriophage fd to Deliver MAGE-A10 or MAGE-A3 HLA-A2-Restricted Peptides and to Induce Strong Antitumor CTL Responses
J. Immunol., March 15, 2008; 180(6): 3719 - 3728.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Parra-Lopez, J. M. Calvo-Calle, T. O. Cameron, L. E. Vargas, L. M. Salazar, M. E. Patarroyo, E. Nardin, and L. J. Stern
Major Histocompatibility Complex and T Cell Interactions of a Universal T Cell Epitope from Plasmodium falciparum Circumsporozoite Protein
J. Biol. Chem., May 26, 2006; 281(21): 14907 - 14917.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, G. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, et al.
MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma
J. Immunol., March 1, 2005; 174(5): 3080 - 3086.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Bricard, H. Bouzourene, O. Martinet, D. Rimoldi, N. Halkic, M. Gillet, P. Chaubert, H. R. MacDonald, P. Romero, J.-C. Cerottini, et al.
Naturally Acquired MAGE-A10- and SSX-2-Specific CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma
J. Immunol., February 1, 2005; 174(3): 1709 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al.
Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses
Clin. Cancer Res., February 1, 2004; 10(3): 929 - 937.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz
Natural T Cell Immunity against Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. D. Puente Navazo, D. Valmori, and C. Ruegg
The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production
J. Immunol., December 1, 2001; 167(11): 6431 - 6440.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Weijzen, S. C. Meredith, M. P. Velders, A. G. Elmishad, H. Schreiber, and W. M. Kast
Pharmacokinetic Differences Between a T Cell-Tolerizing and a T Cell-Activating Peptide
J. Immunol., June 15, 2001; 166(12): 7151 - 7157.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.